Cite

HARVARD Citation

    Peled, N. et al. (2020). GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. Lung cancer. pp. 48-54. [Online]. 
  
Back to record